Affimed N.V. · OTC:AFMDQ
Affimed — Q3 2024 Earnings Presentation
13 slides from Affimed's earnings presentation, 2024
Slide 1: Harnessing the Potential of the Innate Immune System for Oncology
HARNESSING THE POTENTIAL OF THE INNATE IMMUNE SYSTEM FOR ONCOLOGY NASDAQ: AFMD Q3 2024 Business & Financial Update
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation and the accompanying oral commentary contain “forward-looking” statements that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this presentation and the accompanying oral commentary, inclu
Slide 3: AFM24: ICE in EGFR+ Solid Tumors
AFM24 ICE® in EGFR+ Solid Tumors
Slide 4: AFM24-102: Phase 2 Study of AFM24 in Combination with PD-L1 in EGFR+ NSCLC
AFM24-102: Phase 2 Study of AFM24 in Combination with PD-L1 Focused on Advanced EGFR+ NSCLC Current Status • Efficacy EGFRwt1: 4/17 confirmed responses, PFS of 5.9M; 3 of 4 responses ongoing at >7 M • Efficacy EGFRmut2: 4/17 confirmed responses; 8/17 patients continue on treatment with 4/4 responder
Slide 5: Acimtamig: ICE for CD30+ Lymphomas
Acimtamig ICE® for CD30+ Lymphomas
Slide 6: LuminICE-203: Phase 2 Study of Acimtamig with NK Cells in r/r Hodgkin Lymphoma
LuminICE-203: Phase 2 Study of Acimtamig (AFM13) in Combination with NK Cells in r/r Hodgkin Lymphoma Current Status • Efficacy1: ORR of 83.3% (10/12) r/r HL patients, including 6 CRs (50%) • Safety: Manageable safety profile • Benchmark2: ORR: 5-15%, PFS: n.a. Data update at ASH 2024: Efficacy and
Slide 7: AFM28: ICE in AML
AFM28 ICE® in AML @nereimeD
Slide 8: AFM28-101: Phase 1 Dose-Escalation Trial in r/r AML
AFM28-101: Phase 1 Monotherapy Trial Dose-escalation of AFM28, a CD123 Bispecific ICE® in r/r AML Recent Progress for AFM28-101 • Efficacy1: 4/12 patients with CR/Cri at doses of 250mg and 300mg • Efficacy: At DL6, CRc of 50% (3/6) à completed recruitment of additional 6 patients at DL6 • Safety: No
Slide 9: Michael Wolf, Vice President, Finance
Michael Wolf Vice President, Finance
Slide 10: Selected Balance Sheet and Cash Flow Metrics
Selected Balance Sheet and Cash Flow Metrics Balance Sheet As of As of September 30, 2024 December 31, 2023 (millions of €) (millions of €) Total Cash, Cash Equivalents & Investments 24.1 72.0 Cash Flow For the quarter ended For the quarter ended September 30, 2024 September 30, 2023 (millions of €)
Slide 11: Selected Income Statement Metrics
Selected Income Statement Metrics For the quarter ended For the quarter ended September 30, 2024 September 30, 2023 (millions of €) (millions of €) Revenue 0.2 2.0 Other Income and expenses – net 0 0 Research and development expense (10.1) (21.5) General and administrative expense (4.3) (5.4) Operat
Slide 12: Three Ongoing Studies with ICE Confirm the Potential of the Innate Immune System
Three Ongoing Studies with ICE® Confirm the Potential of the Innate Immune System in Fighting Cancer Progressed clinical programs to pivotal data readouts • All three assets advanced in the clinic showing promise in relapsed/refractory patients Realized clinical proof of concept for all three ICE® i
Slide 13: Thank you!
Thank you!